1887

Abstract

A comprehensive investigation of invasive was carried out in Brazil as part of the programme of the national epidemiological surveillance system. The investigation provided data on the trends of resistance to antimicrobial agents. A total of 6470 isolates of collected in the country from 1993 to 2004 were tested. During this period of time, the number of penicillin-resistant strains rose from 10·2 to 27·9 %. The proportions of intermediate and high-level resistant strains in 1993, which were 9·1 and 1·1 %, respectively, rose to 22·0 and 5·9 % in 2004. Geometric mean MICs for penicillin increased after the year 2000, to 0·19 μg ml in 2004; most of these isolates were from patients with pneumonia and from children under 5 years old, and belonged to serotype 14. There was a significant increase in the number of isolates belonging to serotypes included in the 7-valent conjugate vaccine from children under 5 years old: from 48·6 % in 1993 to 69·6 % in 2004, mainly related to an increase in the frequency of serotype 14 isolates. From 2000 to 2004, meningitis isolates showed higher resistance rates to cefotaxime (2·6 %) compared to non-meningitis isolates (0·7 %); percentages of isolates resistant to trimethoprim-sulfamethoxazole, tetracycline, erythromycin, chloramphenicol and rifampicin were 65, 14·6, 6·2, 1·3 and 0·7 %, respectively. No levoflaxin resistance was observed. Multidrug resistance was identified in 4·6 % of isolates, of which 3·8 % were resistant to three classes, 0·7 % to four classes and 0·1 % to five classes of antimicrobial agent. The study provides valuable information that may support empirical antimicrobial therapy for severe infections in Brazil, and emphasizes the need for conjugate pneumococcal vaccination.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.46387-0
2006-05-01
2024-03-29
Loading full text...

Full text loading...

/deliver/fulltext/jmm/55/5/567.html?itemId=/content/journal/jmm/10.1099/jmm.0.46387-0&mimeType=html&fmt=ahah

References

  1. Appelbaum P. C. 2002; Resistance among Streptococcus pneumoniae : implications for drug selection. Clin Infect Dis 34:1613–1620 [CrossRef]
    [Google Scholar]
  2. Bashir H. E., Laundy M., Booy R. 2003; Diagnosis and treatment of bacterial meningitis. Arch Dis Child 88:615–620 [CrossRef]
    [Google Scholar]
  3. Biscay W. 2002; The in vivo - in vitro paradox in pneumococcal respiratory tract infections. J Antimicrob Chemother 49:433–436 [CrossRef]
    [Google Scholar]
  4. Brandileone M. C. C., Vieira V. S. D., Casagrande S. T. & 14 other authors; 1997; Prevalence of serotypes and antimicrobial resistance of Streptococcus pneumoniae strains isolated from Brazilian children with invasive infections. Microb Drug Resist 3:141–146 [CrossRef]
    [Google Scholar]
  5. Brandileone M. C. C., Di Fabio J. L., Vieira V. S. D., Zanella R. C., Casagrande S. T., Pignatari A. C., Tomasz A. 1998; Geographic distribution of penicillin resistance of Streptococcus pneumoniae in Brazil: genetic relatedness. Microb Drug Resist 4:209–217 [CrossRef]
    [Google Scholar]
  6. Brandileone M. C. C., Andrade A. L. S., Di Fabio J. L., Guerra M. L. L. S., Austrian R. 2003; Appropriateness of a pneumococcal conjugate vaccine in Brazil: potential impact of age and clinical diagnosis, with emphasis on meningitis. J Infect Dis 187:1206–1212 [CrossRef]
    [Google Scholar]
  7. Brandileone M. C. C., Casagrande S. T., Guerra M. L. S., Zanella R. C., Andrade A. L. S., Di Fabio J. L. 2005; Increase in penicillin resistance of invasive Streptococcus pneumoniae in Brazil after 1999. J Antimicrob Chemother 56:437–439
    [Google Scholar]
  8. Centers for Disease Control & Prevention; 2006; Recommended childhood and adolescent immunization schedule – United States, 2006. Morb Mortal Wkly Rep 54:Q1–Q4
    [Google Scholar]
  9. Clinical Laboratory Standards Institute/National Committee for Clinical Laboratory Standards 2005; Performance Standards for Antimicrobial Susceptibility Testing . Fifteenth Informational Supplement . CLSI/NCCLS document M100-S15 Wayne, PA, USA: Clinical and Laboratory Standards Institute;
    [Google Scholar]
  10. Dagan R., Engelhard D., Piccard E., Englehard D. 1992; Epidemiology of invasive childhood pneumococcal infections in Israel. The Israeli Pediatric Bacteremia and Meningitis Group. JAMA (J Am Med Assoc) 268:3328–3332 [CrossRef]
    [Google Scholar]
  11. Dagan R., Givon-Lavi N., Zamir O., Fraser D. 2003; Effect of a nonavalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers. Pediatr Infect Dis J 22:532–539
    [Google Scholar]
  12. Di Fabio J. L., Homma A., Quadros C. 1997; Pan American Health Organization epidemiological surveillance network for Streptococcus pneumoniae . Microb Drug Resist 3:131–133 [CrossRef]
    [Google Scholar]
  13. Di Fabio J. L., Castañeda E., Agudelo C. I. & 16 other authors; 2001; Evolution of Streptococcus pneumoniae serotypes and penicillin susceptibility in Latin America. SIREVA-Vigia Group; 1993 to 1999 Pediatr Infect Dis J 20:959–977 [CrossRef]
    [Google Scholar]
  14. Doern G. V., Richter S. S., Miller A., Miller N., Rice C., Heilmann K., Beekmann S. 2005; Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes?. Clin Infect Dis 41:139–148 [CrossRef]
    [Google Scholar]
  15. Dowson C. G., Coffey T. G., Spratt B. G. 1994; Origin and molecular epidemiology of penicillin-binding protein-mediated resistance to beta-lactam antibiotics. Trends Microbiol 2:361–365 [CrossRef]
    [Google Scholar]
  16. Facklam R. R., Washington J. A. II 1991; Streptococcus and related catalase-negative Gram positive cocci. In Manual of Clinical Microbiology , 5th edn. pp  238–257 Edited by Balows A., Hausler W. J. Jr, Hermann K. L., Isenberg H. D., Shadomy H. J. Washington, DC: American Society for Microbiology;
    [Google Scholar]
  17. Feikin D. R., Klugman K. P. 2002; Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. Clin Infect Dis 35:547–555 [CrossRef]
    [Google Scholar]
  18. Heffelfinger J. D., Dowell S. F., Jorgensen J. H. & 7 other authors; 2000; Management of community-acquired pneumonia in the era of pneumococcal resistance. Arch Intern Med 160:1399–1408 [CrossRef]
    [Google Scholar]
  19. Kaplan S. L. Jr, Mason E. O., Wald E. R. & 7 other authors; 2004; Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics 113:443–449 [CrossRef]
    [Google Scholar]
  20. Kellner J. D., McGeer A., Cetron M. S., Low D. E., Butler J. C., Matlow A., Talbot J., Ford-Jones E. L. 1998; The use of Streptococcus pneumoniae nasopharyngeal isolates from healthy children to predict features of invasive disease. Pediatr Infect Dis J 17:279–286 [CrossRef]
    [Google Scholar]
  21. Kertesz D. A., Di Fabio J. L., Brandileone M. C. C. & 11 other authors; 1998; Invasive Streptococcus pneumoniae infection in Latin American children: results of the Pan American Health Organization Surveillance study. Clin Infect Dis 26:1355–1361 [CrossRef]
    [Google Scholar]
  22. Klugman K. P. 1990; Pneumococcal resistance to antibiotics. Clin Microbiol Rev 3:171–196
    [Google Scholar]
  23. Klugman K. P. 2002; The successful clone: the vector of dissemination of resistance in Streptococcus pneumoniae . J Antimicrob Chemother 50:1–5
    [Google Scholar]
  24. Klugman K. P., Koornhof H. J. 1988; Drug resistance patterns and serogroups or serotypes of pneumococcal isolates from cerebrospinal fluid or blood, 1979–1986. J Infect Dis 158:959–964
    [Google Scholar]
  25. Klugman K. P., Low D. E., Metlay J., Pechere J. C., Weiss K. 2004; Community-acquired pneumonia: new management strategies for evolving pathogens and antimicrobial susceptibilities. Int J Antimicrob Agents 24:411–422 [CrossRef]
    [Google Scholar]
  26. Mandell L. A., Peterson L. R., Wise R., Hooper D., Low D. E., Schaad U. B., Klugman K. P., Courvalin P. 2002; The battle against emerging antibiotic resistance: should fluoroquinolones be used to treat children?. Clin Infect Dis 35:721–727 [CrossRef]
    [Google Scholar]
  27. McCormick A. W., Whitney C. D., Farley M. M. & 9 other authors; 2003; Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States. Nature 9:424–430
    [Google Scholar]
  28. McGee L., McDougal L., Zhou B. & 8 other authors; 2001; Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the Pneumococcal Molecular Epidemiology Network. J Clin Microbiol 39:2565–2571 [CrossRef]
    [Google Scholar]
  29. Okeke I. N., Laxminarayan R., Bhutta Z. A., Duse A. G., Jenkins P., O'Brien T. F., Pablos-Mendez A., Klugman K. P. 2005a; Antimicrobial resistance in developing countries. Part I: recent trends and current status. . Lancet 5:481–493 [CrossRef]
    [Google Scholar]
  30. Okeke I. N., Klugman K. P., Bhutta Z. A., Duse A. G., Jenkins P., O'Brien T. F., Pablos-Mendez A., Laxminarayan R. 2005b; Antimicrobial resistance in developing countries. Part II: strategies for containment. . Lancet 5:568–580 [CrossRef]
    [Google Scholar]
  31. Oteo J., Lázaro E., Abajo F. J., Baquero F., Campos J. & Spanish members of the European Antimicrobial Resistance Surveillance System; 2004; Trends in antimicrobial resistance in 1968 invasive Streptococcus pneumoniae strains isolated in Spanish hospitals (2001 to 2003): decreasing penicillin resistance in children's isolates. J Clin Microbiol 42:5571–5577 [CrossRef]
    [Google Scholar]
  32. Reinert R. R., Reinert S., van der Linden M., Cil M. Y., Al-Lahham A., Appelbaum P. 2005; Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003. Antimicrob Agents Chemother 49:2903–2913 [CrossRef]
    [Google Scholar]
  33. Schrag S. J., McGee L., Whitney C. G. & 7 other authors; 2004; Emergence of Streptococcus pneumoniae with very-high-level resistance of penicillin. Antimicrob Agents Chemother 48:3016–3023 [CrossRef]
    [Google Scholar]
  34. Simonsen G. S., Tapsall J. W., Allegranzi B., Talbot E. A., Lazzari S. 2004; The antimicrobial resistance containment and surveillance approach – a public health tool. Bull W H O 82:928–934
    [Google Scholar]
  35. Song J. H., Jung S. I., Ki H. K. & 21 other authors; 2004; Clinical outcomes of pneumococcal pneumonia caused by antibiotic-resistant strains in Asian countries: a study by the Asian Network for Surveillance of Resistant Pathogens. Clin Infect Dis 38:1570–1578 [CrossRef]
    [Google Scholar]
  36. Stephens D. S., Zughaier S. W., Whitney C. G. & 9 other authors; 2005; Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of pneumococcal conjugate vaccine: population-based assessment. Lancet 365:855–863 [CrossRef]
    [Google Scholar]
  37. Tunkel A. R., Hartman B. J., Kaplan S. L., Kaufman B. A., Roos K. L., Scheld W. M., Whitley R. J. 2004; Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 39:267–284 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.46387-0
Loading
/content/journal/jmm/10.1099/jmm.0.46387-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error